Frank Hoerning Andersen 1st Investments ' Client Advisory ' Valuation ' Financial Analysis ' Communication ' Equity Research ' Healthcare Specialist:
"Genmab is beefing up on R&D in 2020 primarily driven by investments in epcoritamab (DuoBody-CD3x-CD20) and DuoBody-PD-L1x4-1BB. Therefore earnings outlook for 2020 felt short of market expectations. I believe this is the right move as epcoritamab has a great potential in hematological malignancies. Early data for treatment of lymphoma presented at ASH 2019 indicated a strong efficacy and safety profile. With respect to Darzalex Genmab guides for sales of USD 3.9-4.2bn in 2020 slightly below market expectations. This should not raise concerns as Darzalex sales in 2020 should be propelled by larger impact from early lines of treatment, more patients getting treated with Darzalex and are living longer, and the likely approval of the subcutaneous formulation due in Q2'20".
Kilde: Linkedin
"Genmab is beefing up on R&D in 2020 primarily driven by investments in epcoritamab (DuoBody-CD3x-CD20) and DuoBody-PD-L1x4-1BB. Therefore earnings outlook for 2020 felt short of market expectations. I believe this is the right move as epcoritamab has a great potential in hematological malignancies. Early data for treatment of lymphoma presented at ASH 2019 indicated a strong efficacy and safety profile. With respect to Darzalex Genmab guides for sales of USD 3.9-4.2bn in 2020 slightly below market expectations. This should not raise concerns as Darzalex sales in 2020 should be propelled by larger impact from early lines of treatment, more patients getting treated with Darzalex and are living longer, and the likely approval of the subcutaneous formulation due in Q2'20".
Kilde: Linkedin
